| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1030605683 |
| P356 | DOI | 10.1186/1471-2407-7-203 |
| P932 | PMC publication ID | 2217558 |
| P698 | PubMed publication ID | 17976237 |
| P5875 | ResearchGate publication ID | 5870761 |
| P50 | author | Yung-Jue Bang | Q16180903 |
| Eui Kyu Chie | Q44335316 | ||
| Se-Hoon Lee | Q46883674 | ||
| Seock-Ah Im | Q58821370 | ||
| Dong-Young Noh | Q78317473 | ||
| Do-Youn Oh | Q87569618 | ||
| Tae-You Kim | Q87569625 | ||
| Dae-Seog Heo | Q87569628 | ||
| Woo Kyung Moon | Q88377599 | ||
| Bhumsuk Keam | Q88437935 | ||
| Wonshik Han | Q88853078 | ||
| P2093 | author name string | Jee Hyun Kim | |
| Dong-Wan Kim | |||
| Hee-Jun Kim | |||
| In Ae Park | |||
| Sung Whan Ha | |||
| P2860 | cites work | Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications | Q27860709 |
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up | Q28306437 | ||
| Primary systemic therapy in operable breast cancer: clinical data and biological fall-out | Q31047351 | ||
| TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients | Q33179641 | ||
| Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy | Q33281956 | ||
| Locally advanced breast cancer | Q33654588 | ||
| Towards a novel classification of human malignancies based on gene expression patterns | Q34378411 | ||
| International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations | Q35164084 | ||
| Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer | Q35783094 | ||
| Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy | Q36135680 | ||
| Molecular classification and molecular forecasting of breast cancer: ready for clinical application? | Q36250255 | ||
| Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy | Q36271514 | ||
| Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer | Q36623843 | ||
| Is Nottingham prognostic index useful after induction chemotherapy in operable breast cancer? | Q36671085 | ||
| Current trends and controversies over pre-operative chemotherapy for women with operable breast cancer | Q36698781 | ||
| Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer | Q40553489 | ||
| Breast cancer molecular subtypes respond differently to preoperative chemotherapy | Q42482998 | ||
| Prognostic markers in triple-negative breast cancer | Q42505075 | ||
| The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes | Q42511189 | ||
| Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome? | Q44323220 | ||
| The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. | Q44618276 | ||
| Only grading has independent impact on breast cancer survival after adjustment for pathological response to preoperative chemotherapy | Q44838543 | ||
| Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. | Q46966638 | ||
| A phase II study of neoadjuvant docetaxel plus doxorubicin (KBCS-01) in stage II, III breast cancer. | Q53595796 | ||
| C-erbB2 expression predicts response to preoperative chemotherapy for locally advanced breast cancer | Q59706460 | ||
| Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer | Q61965252 | ||
| A comparative study of the peroxidase-antiperoxidase method and an avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies | Q72635379 | ||
| Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer | Q73042203 | ||
| The analysis of prognostic factors in stage III-B non-inflammatory breast cancer | Q73550925 | ||
| Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology | Q73567658 | ||
| p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients | Q74067210 | ||
| Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS) | Q74604115 | ||
| Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy | Q74611825 | ||
| Effect of preoperative chemotherapy on the outcome of women with operable breast cancer | Q77093352 | ||
| Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18 | Q77438388 | ||
| HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization | Q77624096 | ||
| American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome | Q80996920 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | breast cancer | Q128581 |
| doxorubicin | Q18936 | ||
| docetaxel | Q420436 | ||
| chemotherapy | Q974135 | ||
| P304 | page(s) | 203 | |
| P577 | publication date | 2007-11-01 | |
| P1433 | published in | BMC Cancer | Q326300 |
| P1476 | title | Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer | |
| P478 | volume | 7 |
| Q38458792 | 18 F-fluorodeoxyglucose uptake predicts pathological complete response after neoadjuvant chemotherapy for breast cancer: a retrospective cohort study |
| Q37662215 | A gene expression signature that predicts the therapeutic response of the basal-like breast cancer to neoadjuvant chemotherapy |
| Q51684386 | A meta-analysis of biomarkers for the prognosis of triple-negative breast cancer patients. |
| Q54349347 | A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer. |
| Q55405558 | A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer. |
| Q35051318 | ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy |
| Q36105958 | ALK alteration is a frequent event in aggressive breast cancers. |
| Q37947894 | Adjuvant systemic treatment for individual patients with triple negative breast cancer |
| Q35909551 | Analysis of Clinical Features and Outcome of 356 Triple-Negative Breast Cancer Patients in China |
| Q35651216 | Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients |
| Q89978440 | Antitumor Efficacy of Focused Ultrasound-MFL Nanoparticles Combination Therapy in Mouse Breast Cancer Xenografts |
| Q33851448 | Antitumor activity of Noscapine in combination with Doxorubicin in triple negative breast cancer |
| Q59793503 | Antitumor properties of Salvianolic acid B against triple-negative and hormone receptor-positive breast cancer cells via ceramide-mediated apoptosis |
| Q37809456 | Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists |
| Q27001269 | Bcl-2 expression predicts sensitivity to chemotherapy in breast cancer: a systematic review and meta-analysis |
| Q37180350 | Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response. |
| Q38766037 | Birinapant (TL32711) Improves Responses to GEM/AZD7762 Combination Therapy in Triple-negative Breast Cancer Cell Lines. |
| Q34560725 | Body mass index is not associated with treatment outcomes of breast cancer patients receiving neoadjuvant chemotherapy: korean data |
| Q33575459 | Breast cancer histology and receptor status characterization in Asian Indian and Pakistani women in the U.S.--a SEER analysis |
| Q88328690 | CLR 125 Auger Electrons for the Targeted Radiotherapy of Triple-Negative Breast Cancer |
| Q38465537 | Chemotherapy response assay test and prognosis for breast cancer patients who have undergone anthracycline- and taxane-based chemotherapy |
| Q35803370 | Clinical efficacy of administering oxaliplatin combined with S-1 in the treatment of advanced triple-negative breast cancer |
| Q38451966 | Clinical usefulness of AJCC response criteria for neoadjuvant chemotherapy in breast cancer |
| Q42474341 | Clinicopathological features and treatment strategy for triple-negative breast cancer |
| Q42458534 | Common and discriminative clinicopathological features between breast cancers with pathological complete response or progressive disease in response to neoadjuvant chemotherapy |
| Q36924445 | Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer. |
| Q28271168 | DNA copy number alterations and expression of relevant genes in triple-negative breast cancer |
| Q43430523 | Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer |
| Q34051790 | Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy |
| Q41722410 | Efficacy of neo-adjuvant chemotherapy with TEC regimen on breast cancer |
| Q38461102 | Estrogen receptor status confers a distinct pattern of response to neoadjuvant chemotherapy: implications for optimal durations of therapy: distinct patterns of response according to ER expression |
| Q33710233 | Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotype |
| Q50658602 | Identification of prognostic different subgroups in triple negative breast cancer by Her2-neu protein expression. |
| Q36092026 | Impact of triple-negative breast cancer phenotype on prognosis in patients with stage I breast cancer |
| Q35558914 | Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis |
| Q33573055 | Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy |
| Q45227034 | Molecular Mechanism and Targeted Therapy Options of Triple-Negative (ER, PgR, HER-2/neu) Breast Cancer: Review |
| Q36649503 | Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epirubicin for operable breast cancer: improved prognosis in triple-negative tumors |
| Q84474921 | Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy |
| Q45786239 | Oncologic safety of breast-conserving surgery compared to mastectomy in patients receiving neoadjuvant chemotherapy for locally advanced breast cancer |
| Q36306513 | Outcome of triple-negative breast cancer in patients with or without markers regulating cell cycle and cell death |
| Q34296476 | PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors |
| Q35990463 | Pathological complete response in younger and older breast cancer patients |
| Q42117291 | Pathological tumor response to neoadjuvant chemotherapy using anthracycline and taxanes in patients with triple-negative breast cancer |
| Q37565645 | Pharmacotherapy of triple-negative breast cancer |
| Q46365334 | Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution |
| Q35237197 | Predictive Significance of p53, Ki-67, and Bcl-2 Expression for Pathologic Complete Response after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer |
| Q50850848 | Predictive and prognostic factors in locally advanced breast cancer: effect of intratumoral FOXP3+ Tregs. |
| Q38047337 | Predictive biomarkers in breast cancer: their value in neoadjuvant chemotherapy. |
| Q38465712 | Predictive value of FDG PET/CT for pathologic axillary node involvement after neoadjuvant chemotherapy |
| Q33994633 | Prognostic Factors in Patients with Stage II/III Breast Cancer Treated with Adjuvant Extension of Neoadjuvant Chemotherapy: A Retrospective Cohort Study with Ten-Years of Follow-Up Data |
| Q94571116 | Prognostic Role of Androgen Receptor Expression in Surgically Resected Early Breast Cancer Patients |
| Q37547957 | Prognostic Significance of Inner Quadrant Involvement in Breast Cancer Treated with Neoadjuvant Chemotherapy |
| Q48213913 | Prognostic factors for patients with newly diagnosed brain metastasis from breast cancer |
| Q37113312 | Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: breast cancer subtype analyses |
| Q38770344 | Prognostic values of Ki-67 in neoadjuvant setting for breast cancer: a systematic review and meta-analysis |
| Q37319292 | Reduction of breast cancer relapses with perioperative non-steroidal anti-inflammatory drugs: new findings and a review. |
| Q38420000 | Residual Mammographic Microcalcifications and Enhancing Lesions on MRI After Neoadjuvant Systemic Chemotherapy for Locally Advanced Breast Cancer: Correlation with Histopathologic Residual Tumor Size |
| Q34227524 | SPHK1 regulates proliferation and survival responses in triple-negative breast cancer |
| Q33378965 | The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer |
| Q53063063 | The combination of FDG PET and dynamic contrast-enhanced MRI improves the prediction of disease-free survival in patients with advanced breast cancer after the first cycle of neoadjuvant chemotherapy. |
| Q33480671 | The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens: a case control study |
| Q46842412 | The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer |
| Q53678741 | The sialyl-glycolipid SSEA4 marks a subpopulation of chemotherapy resistant breast cancer cells with mesenchymal features. |
| Q36177748 | Triple negative breast cancer - prognostic factors and survival |
| Q37356185 | Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women |
| Q92859213 | Triple-negative breast cancer: recent treatment advances |
| Q33900930 | Triple-negative breast cancer: role of specific chemotherapy agents |
| Q33986198 | Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer |
| Q45004261 | Unfavorable pathological complete response rate of neoadjuvant chemotherapy epirubicin plus taxanes for locally advanced triple-negative breast cancer |
| Q34328227 | Value of TP53 status for predicting response to neoadjuvant chemotherapy in breast cancer: a meta-analysis |
| Q46079292 | p53 as a specific prognostic factor in triple-negative breast cancer |
Search more.